Division of Pediatric Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons / NewYork-Presbyterian Morgan Stanley Children's Hospital, 3959 Broadway CH2N, New York, NY 10032.
Department of Biostatistics, Columbia University Mailman School of Public Heath, 722 W 168(th) St, New York, NY 10032.
J Pediatr Surg. 2021 May;56(5):905-910. doi: 10.1016/j.jpedsurg.2020.10.008. Epub 2020 Oct 19.
Early presentation and prompt diagnosis of acute appendicitis are necessary to prevent progression of disease leading to complicated appendicitis. We hypothesize that patients had a delayed presentation of acute appendicitis during the COVID-19 pandemic, which affected severity of disease on presentation and outcomes.
We conducted a retrospective review of all patients who were treated for acute appendicitis at Morgan Stanley Children's Hospital (MSCH) between March 1, 2020 and May 31, 2020 when the COVID-19 pandemic was at its peak in New York City (NYC). For comparison, we reviewed patients treated from March 1, 2019 to May 31, 2019, prior to the pandemic. Demographics and baseline patient characteristics were analyzed for potential confounding variables. Outcomes were collected and grouped into those quantifying severity of illness on presentation to our ED, type of treatment, and associated post-treatment outcomes. Fisher's Exact Test and Kruskal-Wallis Test were used for univariate analysis while cox regression with calculation of hazard ratios was used for multivariate analysis.
A total of 89 patients were included in this study, 41 patients were treated for appendicitis from March 1 to May 31 of 2019 (non-pandemic) and 48 were treated during the same time period in 2020 (pandemic). Duration of symptoms prior to presentation to the ED was significantly longer in patients treated in 2020, with a median of 2 days compared to 1 day (p = 0.003). Additionally, these patients were more likely to present with reported fever (52.1% vs 24.4%, p = 0.009) and had a higher heart rate on presentation with a median of 101 beats per minute (bpm) compared to 91 bpm (p = 0.040). Findings of complicated appendicitis on radiographic imaging including suspicion of perforation (41.7% vs 9.8%, p < 0.001) and intra-abdominal abscess (27.1% vs 7.3%, p = 0.025) were higher in patients presenting in 2020. Patients treated during the pandemic had higher rates of non-operative treatment (25.0% vs 7.3%, p = 0.044) requiring increased antibiotic use and image-guided percutaneous drain placement. They also had longer hospital length of stay by a median of 1 day (p = 0.001) and longer duration until symptom resolution by a median of 1 day (p = 0.004). Type of treatment was not a predictor of LOS (HR = 0.565, 95% CI = 0.357-0.894, p = 0.015) or duration until symptom resolution (HR = 0.630, 95% CI = 0.405-0.979, p = 0.040).
Patients treated for acute appendicitis at our children's hospital during the peak of the COVID-19 pandemic presented with more severe disease and experienced suboptimal outcomes compared to those who presented during the same time period in 2019.
III.
早期表现和及时诊断急性阑尾炎对于防止疾病进展为复杂阑尾炎是必要的。我们假设在 COVID-19 大流行期间,急性阑尾炎患者的就诊时间延迟,这会影响就诊时疾病的严重程度和结局。
我们对 2020 年 3 月 1 日至 5 月 31 日期间在摩根士丹利儿童医院(MSCH)接受急性阑尾炎治疗的所有患者进行了回顾性分析,当时 COVID-19 在纽约市(NYC)正处于高峰期。为了比较,我们回顾了 2019 年 3 月 1 日至 5 月 31 日之前大流行期间接受治疗的患者。分析了潜在混杂因素的人口统计学和基线患者特征。收集了结果并分为定量评估我们急诊科就诊时疾病严重程度、治疗类型和相关治疗后结局的指标。使用 Fisher 精确检验和 Kruskal-Wallis 检验进行单变量分析,使用 Cox 回归计算危险比进行多变量分析。
这项研究共纳入了 89 名患者,其中 41 名患者于 2019 年 3 月 1 日至 5 月 31 日期间(非大流行期间)接受了阑尾切除术治疗,48 名患者于 2020 年同期(大流行期间)接受了治疗。与 2019 年相比,2020 年就诊于急诊科的患者症状持续时间明显更长,中位数为 2 天,而 1 天(p=0.003)。此外,这些患者更有可能出现报告的发热(52.1%比 24.4%,p=0.009),就诊时的心率更高,中位数为 101 次/分钟,而 91 次/分钟(p=0.040)。放射影像学检查发现复杂阑尾炎的表现,包括穿孔(41.7%比 9.8%,p<0.001)和腹腔脓肿(27.1%比 7.3%,p=0.025)的比例更高。在 2020 年就诊的患者中,非手术治疗(25.0%比 7.3%,p=0.044)的比例更高,需要增加抗生素使用和影像引导经皮引流。他们的住院时间中位数也更长,为 1 天(p=0.001),症状缓解的时间中位数也更长,为 1 天(p=0.004)。治疗类型并不是住院时间(HR=0.565,95%CI=0.357-0.894,p=0.015)或症状缓解时间(HR=0.630,95%CI=0.405-0.979,p=0.040)的预测因素。
在 COVID-19 大流行高峰期,在我们儿童医院接受急性阑尾炎治疗的患者与 2019 年同期相比,就诊时疾病更严重,结局更不理想。
III。